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Comparison of effectiveness of cefovecin,
doxycycline, and amoxicillin for the
treatment of experimentally induced early
Lyme borreliosis in dogs
Bettina Wagner1, John Johnson2, David Garcia-Tapia2, Nicole Honsberger2, Vickie King2, Catherine Strietzel2,
John M. Hardham2, Thomas J. Heinz2, Richard T. Marconi3 and Patrick F. M. Meeus2*

Abstract
Background: While Koch’s postulates have been fulfilled for Lyme disease; causing transient fever, anorexia and
arthritis in young dogs; treatment of sero-positive dogs, especially asymptomatic animals, remains a topic of debate.
To complicate this matter the currently recommended antibiotic treatments of Lyme Disease in dogs caused by
Borrelia burgdorferi require daily oral administrations for 31 days or longer, which makes non-compliance a concern.
Additionally, there is no approved veterinary antimicrobial for the treatment of Lyme Disease in dogs in the USA
and few recommended treatments have been robustly tested.
In vitro testing of cefovecin, a novel extended-spectrum cephalosporin, demonstrated inhibition of spirochete
growth. A small pilot study in dogs indicated that two cefovecin injections two weeks apart would be as efficacious
against B. burgdorferi sensu stricto as the recommended treatments using doxycycline or amoxicillin daily for
31 days.
This hypothesis was tested in 17–18 week old Beagle dogs, experimentally infected with B. burgdorferi sensu stricto,
using wild caught ticks, 75 days prior to antimicrobial administration.
Results: Clinical observations for lameness were performed daily but were inconclusive as this characteristic sign of
Lyme Disease rarely develops in the standard laboratory models of experimentally induced infection. However, each
antibiotic tested was efficacious against B. burgdorferi as measured by a rapid elimination of spirochetes from the
skin and reduced levels of circulating antibodies to B. burgdorferi. In addition, significantly less cefovecin treated
animals had Lyme Disease associated histopathological changes compared to untreated dogs.
Conclusions: Convenia was efficacious against B. burgdorferi sensu stricto infection in dogs as determined by
serological testing, PCR and histopathology results. Convenia provides an additional and effective treatment option
for Lyme Disease in dogs.
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Background
In North America, Lyme Disease (LD) in dogs is caused by
Borrelia burgdorferi (Bb) sensu stricto a tick-borne spirochete. A diagnosis of LD is made based on an assessment
of tick exposure risk, clinical signs consistent with disease,
serological testing, differential diagnosis and response to
antimicrobial therapy [1]. Clinical signs of LD are generally
non-descript in dogs, but may include fever, arthritis,
anorexia, lymphadenopathy and glomerulonephritis [2, 3].
However, the majority of dogs sero-positive to Bb do not
show clinical signs of the disease [1]. There are no approved
antimicrobials for the treatment of LD in dogs and because
it is difficult to induce clinical disease in dogs by experimental infection, the optimal use of available antibiotics
and duration of treatment are unknown [1]. Not only do
opinions vary on how to treat dogs, but also on whether
or not to treat sero-positive, but asymptomatic dogs.
Additionally, all currently recommended treatments require
frequent and prolonged antibiotic administration which
makes owner non-compliance with the full dosing regimen
a concern [4].
The objective of this study was to compare the outcome
of treatment of beagles experimentally infected with Bb
with cefovecin, a novel long-acting cephalosporin [5, 6],
administered as two subcutaneous injections 14 days apart
to the recommended daily administration of doxycycline
or amoxicillin for 31 days [1]. In this study we used an
“early” LD model that is based on histopathological
changes in joint synovial tissues [7–9]. This model consistently and reliably produces joint lesions which precede
the development of LD induce lameness. The United
States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) has accepted this early LD model
as the primary variable in support of label claims against
subclinical arthritis associated with LD for vaccine registration purposes (CVB. Demonstrating efficacy against
canine Lyme disease. Veterinary Services Memorandum
Draft No. 316, 2007). Clinical signs, serological responses
and the presence or absence of Borrelia spirochete DNA
in skin biopsies were also measured to provide broad and
clinically relevant measurements of response to treatment.
Results
Cefovecin in vitro growth inhibition of spirochetes

Cefovecin at a high concentration of 2 ug/ml eliminates
Borrelia burgdorferi strain B31 by 24–30 h in BSK-H
culture at 34C, and 0.02 ug/ml of cefovecin retards
spirochete growth by at least 30 % in 54 h (Fig. 1). Data
from this limited initial probe study bracket the MIC of
cefovecin against a high pass B. burgdorferi lab strain.
Detection of spirochete DNA in skin biopsies

Polymerase chain reaction (PCR) amplification of the
Borrelia flaB gene confirmed the successful infection of
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Fig. 1 Cefovecin in vitro growth inhibition of Bb viability. Bb viability
in the presence of 0, 0.2 or 2 ug/ml cefovecin was determined at 0,
6, 24, 30, 48, and 54 h by counting motile spirochetes in ten random
field-of-views (FOV) using phase contrast microscopy. Each dose was
assessed in triplicate and the mean calculated; error bars represent
the standard error of the mean (SEM), when error bars are not
shown the SEM is smaller than the symbols

dogs with spirochetes from the wild caught ticks by day
48, with 12 out of 32 dogs having detectable Borrelia
DNA in their skin biopsies. This ratio continued to increase in untreated dogs through day 118, with 6 out of
8 dogs becoming positive, but declined thereafter to
become negative for all untreated dogs by day 180. None
of the treated animals remained PCR positive after treatment with doxycycline, amoxicillin or cefovecin started
on day 75. This difference in frequency was significant
between the untreated controls and the treated groups
on day 118 only. No significant differences were observed between the PCR results of any of the antibiotic
treatment groups.
Clinical signs

For three weeks after tick challenge body temperatures
were measured daily in all dogs. Five to eight dogs in
each group had pyrexia (>39.5 °C) at least one time during that period, but all dogs remained bright and alert.
Only one dog from the untreated group was lame on
day 196 and one dog from the doxycycline-treated group
was lame on day 264.
Serological responses to infection and treatment

Prior to tick infestation (study day −15) all dogs were
serologically negative for Bb-specific antibodies using
several independent assays (Fig. 2). By day 48, i.e., prior
to treatment, 5–7 animals in each group had become
SNAP positive (Fig. 2). The dogs continued to seroconvert even after treatment with the highest number of
SNAP positive dogs observed on day 111, about 15 weeks
after the start of tick infestation and 5 weeks after the
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Fig. 2 Number of Bb sero-positive treated and untreated dogs using different antigens and diagnostic platforms. The number of sero-positive
dogs in each of 4 treatment groups (n = 8) using 4 routinely used commercial assays at different times after infections and treatments. Statistical
analysis was only possible after day 48, because of housing restrictions. Statistical difference of a treatment group from untreated animals is
designated by D (Doxycycline), A (Amoxicillin) and C (Cefovecin)

start of antimicrobial treatments. Subsequently the numbers of SNAP sero-positive dogs in the treated groups
declined to zero by day 221 or around 21 weeks after
the start of the treatment. In contrast, in the untreated
control group only 2–3 dogs became sero-negative on
any given sampling day for the remainder of the study.
The difference in the number of SNAP positive dogs
between untreated and treated animals was significant
on day 145 for the cefovecin group only. By day 221,
however, all antibiotic treated groups had significantly
less sero-positive dogs than the untreated control group.
Also, on Day 145 the cefovecin group had significantly
fewer dogs positive than the doxycycline group. At no
other time was a significant difference observed between
any of the antibiotic treatments used in the number of
SNAP positive dogs.
Antibody values using the Quant C6 assays followed
a similar pattern as the SNAP test and many animals
passed the sero-positive cut-off limits by day 48 (Fig. 2).
In contrast to the SNAP test, however, all treated animals became Quant C6 negative by day 145, irrespective of the antibiotic used. This difference in frequency
was significant on all subsequent sampling days, except

on day 179 when only 4 untreated animals were seropositive.
Antibody values in the Lyme Multiplex assay reflect
the different expression stages of the surface antigens
used. OspA, an antigen expressed in the tick vector, only
stimulated an early and transient serological response
below the positive cut-off level and differences were not
detected in any of the samples (data not shown). OspC,
expressed during transmission of the pathogen from the
tick vector to the mammalian host, generated a serological response early in the infection, but only in half of
the animals. The antibodies to OspC subsequently declined in all animals, including those in the untreated
control group (Fig. 2). No significant differences were
observed between any of the groups at any time point.
By contrast, antibodies to OspF appeared later in the infection, peaking around day 111 in the untreated controls, and only declined upon treatment (Fig. 2). By day
111, all animals in the cefovecin treated group had
already become negative for OspF antibodies, which was
significantly lower than the untreated control group with
only 2 negative animals. At the next sampling point all
amoxicillin and doxycycline treated animals also became
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negative for OspF antibodies, while the number of seronegative untreated controls remained significantly lower
for the rest of the trial with only 2 out of 8 animals.

Histopathological evaluation of skin and joint synovial
tissues

The number of dogs, per treatment group, identified
with lesions consistent with LD is shown in Fig. 3.
Histological sections of healthy skin and joint tissue
(panels a and c), as well as lesions typical associated with
LD (panels b, d, e, f ) found in untreated dogs are show
in Fig. 4. These lesions are characterized by inflammation of the perivascular and perineural tissue in the skin
and by nodular inflammation composed mainly by lymphocytes and plasma cells in the joint capsules. When
considering any lesion as possibly associated with LD, 7
out of 8 control dogs were considered affected, while the
doxycycline, amoxicillin and cefovecin treated groups
only had 3, 4 and 2 affected animals, respectively (Fig. 3).
This reduction in affected animals, when compared to
the untreated controls, was only significant in the cefovecin treated group. When only taking into account
those animals that had at least 3 tissues affected with LD
associated lesions, as a means to remove normal background changes in the joints, both doxycycline and the
cefovecin treated groups achieved significance when
compared to the untreated controls (Fig. 3). The amoxicillin treated group never achieved a significant reduction in the number of affected animals when compared
to the controls, nor was any significant difference observed between any of the treatment groups.

Fig. 3 Number of dogs with lesions associated with Lyme Disease.
The number dogs with any lesions associated with LD in tissue
samples from the joint capsule or synovium from left and right
shoulder, elbow, carpus, stifle, and tarsus of each dog or dogs with
lesions in more than 3 tissues was determined in each treatment
group on day 315. *Statistically different treated dogs from
untreated animals
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Discussion
The purpose of this study was to evaluate the clinical
effectiveness of cefovecin against early LD in an experimental model using wild caught ticks. While the presence of other pathogens cannot be excluded in these
wild caught ticks, the presence of B. burgdorferi sensu
stricto, general considered as the causative agent of LD,
was confirmed in both ticks and dogs. Screening MIC
data for a number of leptospira species and a small pilot
study conducted at Zoetis suggested that cefovecin at
the FDA registered dose (8 mg/kg) and interval (2 doses
at 14 days interval) would be effective. To bridge the
current results to previous studies [10, 11] and to compare cefovecin to the antibiotics currently considered
the standard of care [1] we also included doxycycline
and amoxicillin treatments in this study.
Given that predictably eliciting overt clinical disease,
such as lameness, in dogs in an experimental model has
eluded researchers to date [7, 8, 12], we relied in this
study on evaluating the presence or absence of the pathogens using PCR amplification of Borrelia DNA in skin
biopsies, serological responses and histopathological
changes in skin and joint tissue to test the effectiveness
of the antibiotics.
As observed previously, very few dogs in this study
developed clinical signs associated with LD. Only two
dogs became transiently lame: one dog from the untreated group on day 196 post Bb exposure and one dog
189 days after treatment with doxycycline. The lack of
overt clinical signs occurred despite successfully infecting
all 32 dogs as evidenced by the presence of Bb-specific
antibodies in at least one serological test (SNAP, Quant C6
or Multiplex) or a positive PCR from skin biopsies. Review
of the individual histopathology results in the two dogs
with lameness revealed that only 2 of 10 joints examined,
the right stifle and the left tarsus, had any lesions compatible with those described for LD in the doxycycline treated
dog, with all lesions characterized as mild. However, the
untreated control dog had lesions compatible with those
described for LD in 9 out of 10 joints examined, with
lesions in 4 of these joints; the right carpus, the left
shoulder, and the left and right tarsus; characterized as
moderate to marked in severity.
Similar serological responses to infection and treatment were observed across all diagnostic platforms and
antigens used. Differences observed are associated with
the change in expression of antigens by the Borrelia
spirochetes as they transition from the tick vector to the
mammalian host and subsequently adapt to the host and
its mounting immune response [13]. As such antibodies
to OspC, a surface antigen associated with the initial invasion of the dogs, appear early in the infection only and
antibody values drop typically by 6–8 weeks post infection [13]. Treatment in this study started on day 75 post
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Fig. 4 Characteristic histopathological lesions in subdermis and synovial joint capsules of treated and non-treated animals challenged with Bb.
Non-affected skin-subdermis and synovial capsule are depicted in panels (a) and (c) respectively. Panel b shows a section of subdermis with
minimal inflammation in the perivascular and perineural tissue (pointed by the solid arrow). Note the absence of this infiltrate in (a). Panels d to f
show inflammatory changes observed in joint capsule from three different dogs. The solid arrows point at areas with mononuclear inflammation.
Note the nodular appearance of the inflammation composed mainly by lymphocytes and plasma cells in panel (e). The dashed arrows point at
the synovial layer, which is composed by a single-cell layer in the tissue in panel (c). Note the absence of inflammatory infiltrate in this tissue. All
pictures were taken at a 400 x total magnification

tick exposure. As expected, antibodies to OspC subsequently increased after infection and had started to drop
in all groups, including the untreated control group by
the next sampling time point on day 111 post infection.
OspC is therefore an excellent marker for early or recent
infection, but on its own is not suited to measure the response to treatment that is applied as late into infection
as in this study. By contrast, both the C6 and OspF antigens are expressed during later infection and appear to
be good markers to measure treatment success [13–15].
Antibodies to both markers remain relatively high and
above the sero-positive cut-off limits in many untreated
control animals for at least 300 days after infection. In

contrast, the antibiotic treated groups no longer had substantial antibodies circulating to these antigens within
70 days of antibiotic treatment. While the pathogenesis
and the role of circulating antibodies of LD associated
protein-losing nephropathy remains unclear [1, 16–19]
the significant reduction in circulating antibodies to Bb
antigens might provide clinical benefits [19, 20] and is
considered an indicator of a reduced bacterial burden.
Inflammation in the synovium or in joint capsules along
with hypertrophy/hyperplasia of the synovial layer has
been observed in dogs diagnosed with experimental LD
and these lesions are considered to be precursors to the
lameness typically associated with the infection [8, 12]. In
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this study the cefovecin-treated group had the fewest
number of dogs with lesions and this number was significantly lower than the untreated controls. Given that both
doxycycline and amoxicillin are generally considered as efficacious against Borrelia [1] and given the relatively small
number of dogs per group, it is not surprising that no significant difference was observed between any of the antibiotic treatment groups. While it is encouraging that even
225 days after the last cefovecin treatment significantly
less treated animals had joint lesions associated with LD,
this study did not assess the longer term benefits of treatment. In previous studies Borrelia antibodies rose again
150–180 days after a 30 day treatment with amoxicillin or
doxycycline [21], suggesting that the infection had not
been eliminated from the animals and that the possibility
of clinical and pathological relapse remained. While we
did not observe such rise in this study, we cannot exclude
that longer observations or immune-suppression with corticosteroids [11] might be necessary to determine whether or
not the pathogens were eliminated from the animals or not.

Conclusions
Cefovecin administered as two subcutaneous injections
at 8 mg/kg body weight 14 days apart provided a significant and sustained reduction in the numbers of dogs
with joint lesions and circulating antibodies associated
with LD infection. This outcome was comparable to that
observed with 31 days of daily oral doxycycline or
amoxicillin administration.
Methods
Ethics

The study and the experimental design were approved
by the Zoetis Institutional Animal Care and Use Committee (IACUC).
In vitro testing of Cefovecin

Borrelia burgdorferi strain B31 (ATCC 35210) spirochetes were grown at 34 °C under microaerophilic conditions in modified Barbour-Stoenner-Kelly (BSK-H)
Medium Complete (Sigma, St. Louis, MO, USA). Because minimum inhibitory concentrations of most 3rd
generation cephalosporins against a variety of Borrelia
species fall within ≤0.015 and 0.125 mcg/ml [22–25], a
low and high concentration approximately covering this
range were selected for testing. Cefovecin 100X stocks
were prepared in water and sterile-filtered (0.22 micron).
The same volume of each stock solution, 40 ul, was
added to 4 ml of spirochetes in media for final cefovecin
dilutions of 0, 0.02 and 2.0 mcg/ml. Triplicates were prepared for each of the three treatments and monitored
for growth over a three day period. Time points for sampling were at 0, 6, 24, 30, 48, and 54 h. Spirochete viability in each sample was based on total motile spirochetes
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by counting ten random field-of-views (FOV) via phase
contrast microscopy [26].
Animals

Thirty-two healthy, purpose-bred, 17–18 week old Beagle
dogs were used in this study. The animals received all routine vendor specific and Zoetis site specific vaccinations;
but care was taken to exclude vaccines against LD or
leptospirosis. All dogs were also tested, 15 days prior to
experimental tick exposure, for antibodies to Bb using the
SNAP assay and found to be negative.
Study groups, tick exposure and antimicrobial treatment

This was a prospective, masked, randomized study in
dogs experimentally infected with Bb. Dogs were acclimated to the Zoetis study facility for at least seven days
prior to the start of study activities. Prior to day 0 dogs
were allocated to treatments and runs according to a
randomization plan produced by a Zoetis Biometrician
using a split-plot design with a completely random design in the whole plot (sex) and a randomized complete
block in the split-plot (treatment) in multiple rooms. For
the duration of the tick infestation period the dogs were
housed individually to avoid removal of ticks. On study
day 55, after the infestation period and before the treatment period, the dogs were moved to dual housing
based on sex (male-male and female-female) to allow for
more social interaction for the duration of the study as
recommended by Zoetis standard operating procedures
for long term studies.
In April of 2010, study day 0, all 32 dogs were individually exposed to 20 male and 20 female adult Ixodes
scapularis collected in the field from southern Rhode
Island, USA, during the fall of 2009. The percentage of
ticks infected with Bb was 57 %, as determined by direct
fluorescent microscopy and using labelled Bb antibodies
as previously described [27]. The ticks were placed on
the back of the dogs and allowed to attach freely. No
count of attached ticks was made to reduce the manipulation of animals and ticks, and dogs were further fitted
with Elizabethan collars during the tick infestation
period to avoid the removal of the ticks through grooming. Ticks were allowed to feed until repletion. At the
end of the challenge phase, all still attached ticks were
removed and dogs were treated with two applications of
a topical acaricide (Frontline®, Merial) on days 10 and 68
of the study.
On day 68 all animals were weighed to determine individual doses for each antimicrobial used. Subsequently,
beginning on day 75, dogs allocated to the treatment
groups started to receive antimicrobial treatment. The
four treatment groups were (n = 8 per group): untreated;
doxycycline (50 mg Vibramycin®, or 100 mg Vibra-tabs®
West-ward Pharmaceuticals) orally once daily at 10 mg/
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kg for 31 days; amoxicillin (Amoxi-Tabs®, Zoetis) orally
three times a day at 20 mg/kg for 31 days; and cefovecin
sodium (Convenia®, Zoetis) at 8 mg/kg body weight by
subcutaneous injection in two doses, 14 days apart. One
dog in the amoxicillin treatment group was dosed incorrectly, receiving 75 mg rather than 150 mg, on four occasions out of a total of 93 treatments for this dog.
Review of the antibody and histopathological data suggest that this had no influence on the overall treatment
efficacy and as such the animal was included in the overall analysis.
Examination of clinical signs and sample collection

Dogs were observed daily for general health using
standard terms to record any abnormalities. Dog body
temperatures were recorded for three weeks following
the end of tick infestation (day 11 through day 32). Dogs
were, in addition and specifically, observed daily for the
presence or absence of lameness.
On days 48 and 49 (pre-treatment), blood samples
were collected for the purpose of determining infection
status of dogs using SNAP, Quant C6, and Lyme Multiplex assays. Additionally, two skin punch biopsies were
collected from each dog in the dorsal cervical region,
near the site where the ticks were released onto the animal.
Biopsies were taken using a 4 mm punch biopsy under sedation using Dexdomitor® (dexmedetomidine hydrochloride;
Zoetis) and Antisedan® (atipamezole hydrochloride; Zoetis)
for reversal. The first punch biopsy was placed in BarbourStoenner-Kelly II (BSK II) medium for bacterial culture
(data not shown) and the second was immediately frozen
by placement on dry ice and stored at −20 °C until DNA
isolation and PCR were performed as described [28].
Post-treatment blood samples for serum collection were
obtained monthly (days 111, 145, 179, 221, 251, 281, 314)
and post-treatment skin biopsies and PCR were performed on days 118, 146, 180 and at the end of the study
on day 315.
Serology and histopathology

Serum samples were used to determine antibodies to Bb
by SNAP® 4Dx® Test; IDEXX, Westbook, ME (SNAP)),
a quantitative ELISA (Lyme Quant C6® Test; IDEXX
Westbook, ME (Quant C6)), and the Canine Lyme Multiplex assay (Animal Health Diagnostic Center, College of
Veterinary Medicine, Cornell University) as previously described [13]. The latter assay was used to evaluate antibodies against Bb outer surface protein (Osp) A, C, F, and
C6 as previously described [13]. Post mortem samples
were collected on day 315 from skin near the tick application site and samples from the joint capsule or synovium
from left and right shoulder, elbow, carpus, stifle, and tarsus of each dog were collected and placed in 10 % buffered
formalin, and submitted to MPI Research (Mattawan, MI)
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for histological processing. After fixation, the tissues were
trimmed, embedded, sectioned, mounted on glass slides
and stained with H&E. Tissues were evaluated using light
microscopy by a veterinary pathologist blinded as to the
assignment of animals to group or treatment. Descriptive
observations were entered into a datasheet indicating the
presence and severity of each of the lesions in each tissue.
Data analysis

Data summaries and analyses of antimicrobial efficacy
were done using SAS Release 9.2.2 (SAS Institute, Cary,
NC). All hypothesis tests, for data after day 75, were
conducted at the 0.05 level of significance (two-tailed).
Animals were considered positive for Quant C6 (U/mL)
if the value was ≥ 30, positive for Multiplex (median fluorescent intensity (MFI)) OspC if the values were ≥ 1000
and positive for Multiplex OspF if the values were ≥ 1500.
Frequency distributions for sero-conversion data as detected by SNAP (positive, negative), Quant C6 and Multiplex OspC and OspF were calculated for each treatment
and time point. Sero-conversion data were compared
between treatment groups at each time point using
Fisher’s Exact test.
Frequency distributions for biopsy PCR were calculated
for each treatment and time. Biopsy PCR data were compared between treatment groups at each time point using
Fisher’s Exact test. Frequency distributions of the presence/
absence of histopathological changes in the joint/tissue
samples associated with Borrelia infection were calculated
for each treatment and joint/tissue. It was determined for
each dog whether or not the animal had any joint/tissues
with histopathological changes and whether or not the animal had three or more joints/tissues with histopathological
changes. Frequency distributions of these variables were
calculated for each treatment and compared using Fisher’s
Exact test.
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